EMD527040|cas:851333-14-7|西域试剂

EMD527040,99.94%

产品编号：Bellancom-101473| CAS NO：851333-14-7| 分子式：C₂₉H₃₂Cl₂N₄O₅| 分子量：587.49

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101473		￥4800.00	杭州北京（现货）
Bellancom-101473		￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

EMD527040

产品介绍

EMD527040 是一种高效和高选择性的 αvβ6 拮抗剂，具有抗纤维化活性。EMD527040 可用于肝癌和肝纤维化研究。

生物活性

EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.

体外研究

EMD527040 inhibits binding of recombinant αvβ6 to fibronectin at 6 nM as compared to >9.5 μM for αvβ3 and αvβ5 integrins (IC50₅₀).
EMD527040 inhibits the attachment of αvβ6 expressing cells (UCLAP3 cells) to fibronectin at IC₅₀ of 1.6 μM, as compared to >50 μM for αvβ3 and αvβ5 integrins.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

EMD527040 (intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL) attenuates bile ductular proliferation and peribiliary collagen deposition by 40-50%, induces downregulation of fibrogenic and upregulation of fibrolytic genes, and improves liver architecture and function. EMD527040 significantly reduced liver and spleen weights by 22% and 50%, respectively in Mdr2(Abcb4)^-/- mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male adult Wistar rats
Dosage:	20-60 mg/kg
Administration:	Intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation)
Result:	Ameliorated fibrosis progression in rodents with biliary fibrosis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male adult Wistar rats
Dosage:	20-60 mg/kg
Administration:	Intraperitoneal injection; 20-60 mg/kg; week 2 to 6 after BDL (bile duct ligation)
Result:	Ameliorated fibrosis progression in rodents with biliary fibrosis.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (170.22 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7022 mL	8.5108 mL	17.0216 mL
5 mM	0.3404 mL	1.7022 mL	3.4043 mL
10 mM	0.1702 mL	0.8511 mL	1.7022 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.26 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.26 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.26 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。